FIELD: medicine, pharmaceutics.
SUBSTANCE: present invention refers to organic chemistry, namely to new specific pyrido[2,3-b]pyrazine derivives specified in cl. 1, to a pharmaceutical composition of the compound according to cl.1, to using the compound according to cl.1, and to a kit for treating or preventing the above pathological conditions on the basis of the compound according to cl.1.
EFFECT: there are prepared new pyrido[2,3-b]pyrazine derivatives effective in treating oncological diseases.
29 cl, 3 tbl, 366 ex
| Title |
Year |
Author |
Number |
| PYRIDOPYRAZINE DERIVATIVES, PHARMACEUTICAL COMPOSITION AND METHOD OF TREATING OR PREVENTING PHYSIOLOGICAL AND/OR PATHOPHYSIOLOGICAL CONDITIONS BY INHIBITION OF ENZYMES ERK, ERK1, ERK2, PI3K, PI3Kalpha, PI3Kbeta, PI3Kgamma, PI3Kdelta, PI3K-C2alpha, PI3K-C2beta, PI3K-Vps34p (VERSIONS) |
2006 |
- Gjunter Ehkkhard
- Klaus Ehkkhard
- Polimeropulos Ehmmanuehl'
- Sajpelt Irehn
- Chek Majkl
- Shuster Til'Man
|
RU2515944C9 |
| PYRIDO[2,3-b]PYRAZINE DERIVATIVES, MEDICINE FOR TREATMENT OF DISEASES OR ABNORMALITIES CAUSED BY MISDIRECTED CELLULAR SIGNAL TRANSDUCTION PROCESSES, METHOD OF MEDICINE OBTAINING |
2004 |
- Viksler Ljudmila
- Gjunter Ehkkhard
- Zejpel'T Irehna
- Klaus Ehkkhard
- Rapp Ul'F-R.
|
RU2330851C9 |
| RAPAMYCIN TARGET INHIBITOR IN MAMMALIAN CELLS, PHARMACEUTICAL COMPOSITION AND USE THEREOF |
2019 |
- Ksia, Mingyu
- Zhao, Ksiaofeng
- Dzhiang, Ksyunlej
- Dzhiang, Ksyundong
|
RU2768583C2 |
| APOPTOSIS-INDUCING MEANS |
2011 |
- Niitsu Joshiro
- Nishita Khiroki
|
RU2639459C2 |
| COMBINATION OF (A) PHOSPHOINOSITIDE-3-KINASE INHIBITOR AND (B) Ras/Raf/Mek PATHAWAY MODULATOR |
2009 |
- Garsija-Ehcheverrija Karlos
- Mera Sove-Mishel'
- St'Juart Darrin
- Vi S'Jusan
- Frich Kristine
- Nejdzhel Tobi
|
RU2508110C2 |
| COMPOSITIONS BASED ON SHP2 INHIBITOR AND METHODS OF CANCER TREATMENT |
2018 |
- Nichols, Robert J.
- Goldsmith, Mark A.
- Schulze, Christopher
- Smith, Jacqueline
- Wildes, David E.
- Kelsey, Stephen
- Singh, Mallika
|
RU2805355C2 |
| METHODS AND COMPOSITIONS APPLICABLE FOR MODULATION OF ANTIOGENESIS USING PROTEIN KINASES RAF AND RAS |
2000 |
- Khud Dzhon
- Ilajsiri Brajan
- Cheresh Dehvid A.
|
RU2257911C2 |
| SELECTION OF MEDICATIONS FOR LUNG CANCER THERAPY BY MEANS OF ANTIBODY-BASED MATRICES |
2008 |
- Singkh Sharat
- Kharvi Zhanna
|
RU2519647C2 |
| THERAPEUTIC COMBINATIONS CONTAINING RAF INHIBITOR AND ERK INHIBITOR |
2017 |
- Caponigro, Giordano
- Meyer, Matthew John
- Cooke, Vesselina
- Stuart, Darrin
|
RU2774612C2 |
| COMBINATIONS OF PI3K INHIBITOR AND MEK INHIBITOR |
2010 |
- Marshija Belvin
- Ajris T. Chan'
- Lori Fridman
- Klaus P. Kheflikh
- Dzhon Preskott
- Dzheffri Uollin
|
RU2563193C2 |
